The destruction of articular cartilage in immune inflammatory arthritic disease involves the proteolytic degradation of its extracellular matrix. (21, (26) (27) (28) , and induction of the cytokines IFNy, TNFa, and IL-1IB (20, 29-1. Abbreviations used in this paper:
Introduction
The destruction of articular cartilage in immune inflammatory arthritic disease involves the proteolytic degradation of its extracellular matrix. The role of activated matrix metalloproteinases (MMPs) in the chondrodestructive process was studied by identifying a selective cleavage product of aggrecan in murine arthritis models initiated by immunization with either type II collagen or proteoglycan. We conducted semiquantitative immunocytochemical studies of VDIPEN34' using a monospecific polyclonal antibody requiring the free COOH group of the COOH-terminal Asn for epitope detection. This antibody recognizes the aggrecan G1 domain fragment generated by MMP [i.e., stromelysin (SLN) or gelatinase A] cleavage of aggrecan between Asn3Il-PheM2 but does not recognize intact aggrecan.
VDIPEN was undetectable in normal mouse cartilage but was observed in the articular cartilage (AC) of mice with collagen-induced arthritis 10 d after immunization, without histological damage and clinical symptoms. This aggrecan neoepitope was colocalized with high levels of glycosaminoglycans (GAGs) in pericellular matrices of AC chondrocytes but was not seen at the articular surface at this early time. Digestion of normal (VDIPEN negative) mouse paw cryosections with SLN also produced heavy pericellular VDIPEN labeling. Computer-based image analysis showed that the amount of VDIPEN expression increased dramatically by 20 d (70% of the SLN maximum) and was correlated with GAG depletion. Both infiltration of inflammatory cells into the synovial cavity and early AC erosion were also very prominent at this time. Analysis of adjacent sections showed that both induction of VDIPEN and GAG depletion were strikingly codistributed within sites of articular cartilage damage. Similar results occurred in proteoglycan-induced arthritis, a more progressive and chronic model of inflammatory arthritis. These studies demonstrate for the first time the MMP-dependent catabolism of aggrecan at sites of chondrodestruction during inflammatory arthritis. (J. Clin. Invest (9) , is elevated in synovial fluids and cartilage of RA and osteoarthritic (OA) patients, and may be up-regulated in synoviocytes and chrondrocytes (10) (11) (12) (13) (14) .
Experimental animal models of inflammatory arthritis have provided important insights for understanding human arthritis. Although the pathological mechanisms of type II collagen-induced (CIA) and PG-induced (PGIA) arthritis are different and not fully understood, both appear to be sustained by genetically controlled autoimmune responses to cartilage ECM components (15) (16) (17) (18) (19) (20) (21) . These models share many similarities with human RA and ankylosing spondylitis, such as humoral and cellular immune responses to immunizing and self-antigens, mononuclear cell infiltration of the synovium, formation of an erosive pannus, and progressive loss of PG and destruction of articular cartilage (18) (19) (20) 22) . The pathogenesis of CIA and PGIA appears to be dependent on binding of PG or CII antibodies to joint cartilage followed by C5a release (23) (24) (25) , activation of autoreactive T cells to matrix components (21, (26) (27) (28) , and induction of the cytokines IFNy, TNFa, and IL-1IB (20, (29) (30) (31) (32) . Of these, IL-1p appears to be very important because neutralizing antibodies ameliorate the histopathology and clinical symptoms in CIA (33) (34) (35) and because IL-1,6 induces SLN and CLN in putative target cells (36) . SLN has been detected in CIA and in experimental arthritis induced by the intraarticular injection of IL-1,6 (22, 37, 38) .
Because all MMPs are secreted as latent zymogens (10, 11, 39, 40) and the activities of mature MMPs are regulated by tissue inhibitors of , it is difficult to determine which of the expressed MMPs are active in RA. SLN and GLN-A cleave aggrecan in the interglobular domain between amino acid residues Asn l and PheM2, generating a hyaluronan-binding GI fragment with the COOH-terminal sequence VDIPEN, which remains bound to hyaluronan in cartilage (7) . Generation and accumulation of this VDIPEN neoepitope, which is common to both human and murine aggrecans (44, 45) , can thus provide a convenient marker of MMP activity in cartilage. An antibody recognizing this COOH-terminal aggrecan neoepitope has been developed; it does not recognize the VDIPEN sequence when it is an integral part of the peptide VDIPENFFGVG (46, 47) . Because of this specificity, anti-VDIPEN IgG does not recognize intact aggrecan but does detect the Gi fragment generated by SLN or GLN-A. The purpose of our experiments was to determine whether the VDIPEN neoepitope is induced and localized in articular cartilage lesions as an early indicator of MMP activity in autoimmune murine models of inflammatory arthritis.
Methods
Animals. CIA was generated in BIO.RIII mice (bred at Mayo Clinic) by injecting a single dose of highly purified porcine CII in CFA subcutaneously, as previously described (48 6 .0, containing the above proteinase inhibitors. After dialysis, the sample was centrifuged and the aggrecan/hyaluronan complex containing supernatent fractionated through an associative cesium chloride density gradient (starting density 1.5 gm/ml) (49) . The bottom fourth of the gradient (Al) was harvested and digested with protease-free chondroitinase ABC and keratanase II (Seigagaku America, Rockville, MD) as follows. Samples (100 jl) in 0.1 M sodium acetate buffer, pH 8.0, were brought to 10 mM EDTA and treated with 0.02 U protease-free chondroitinase ABC overnight at 37°C. Keratanase I (0.1 U) was then added to each sample and incubated at 37°C for 2 h. Samples (1 paw per lane) were then electrophoresed through 4-20% SDS polyacrylamide Tris-glycine gels under reducing conditions and transferred to nitrocellulose. To eliminate nonspecific binding of antibodies, the nitrocellulose was incubated in 5% nonfat dry milk for 1 h at room temperature. The membranes were incubated in a 1:3,000 dilution of anti-VDIPEN antiserum for 1 h at room temperature. The membranes were then washed and incubated with a 1:1,000 dilution of biotinylated-goat anti-rabbit IgG for 1 h at room temperature. Blots were washed and incubated with 1:1,000 dilution of alkaline phosphatasestreptavidin followed by 5-bromo-4-chloro-3-indolyl phosphate nitroblue tetrazolium (Kirkegaard and Perry, Inc., Gaithersburg, MD) to detect immunoreactive bands.
Immunoperoxidase microscopy. Cryofixation was selected as the primary fixation procedure to minimize epitope denaturation that usually accompanies chemical cross-linking and to limit PG extraction resulting from prolonged exposure of cartilage to aldehyde fixatives (50) . Midsagittal 5-jim cryostat sections were cut through the fully calcified unfixed hind paws with a carbide knife. Cryosections were then mildly fixed for 20 min with Nakane solution (periodate/lysine/paraformaldehyde) (5 1 ) and treated with 3% H202 in methanol to inactivate endogenous peroxidases, followed by 0.1% Triton-X 100 in PBS to increase permeability. To facilitate antibody penetration into cartilage (52), some sections were also digested with protease-free chondroitinase ABC (0.02 U, 30 mM Na acetate, 0.1 M Tris-HCl, pH 8.0; Seigagaku America) before fixation. Because chondroitinase ABC has a pH optimum of 8.0 for removal of chondroitin sulfate from proteoglycans, whereas that for hyaluranan digestion is 6.0, use of an alkaline pH greatly reduces hyaluronan cleavage and consequently circumvents possible release of aggrecan or aggrecan fragments from the sections (see Results). The VDIPEN neoepitope was labeled with rabbit anti-VDIPEN IgG (46) that was affinity-purified on VDIPEN-conjugated Reactigel (Pierce, Rockford, IL). An optimal staining concentration of 10 jg/mi IgG was determined in titration experiments conducted on SLN-treated cryosections of normal murine paws. Bound antibodies were detected via immunoperoxidase microscopy using the ABC technique (Elite kit, Vector Labs., Inc., Burlingame, CA). Peroxidase reaction product was developed with a glucose oxidase/diaminobenzidine/nickel method to provide maximum sensitivity (53); 1% Orange G was used as a counterstain. For specificity controls, the primary antibody was incubated with either the neoepitope peptide (H2N-YTGEDFVDIPEN-COOH) or a peptide that spans the neoepitope cleavage site (H2N-YTGEDFVDI-PENFFGV-COOH) and clarified before staining. Peptides were synthesized on an Applied Biosystems 430A peptide synthesizer and purified VDIPEN, An Aggrecan Neoepitope Induced in Inflammatory Arthritis by reversed-phase HPLC on a Waters C18 Deltapak column. All peptides were > 95% pure by reversed-phase HPLC, and the structure of each was confirmed by electrospray ionization mass spectrometry. Preimmune rabbit IgG served as an additional negative control. For positive controls, unfixed paw cryosections were digested with activated recombinant human SLN (100 og/ml in 150 mM NaCl, 25 mM TrisHCl, 10 mM CaCl2, 0.05% Brij-35, pH 7.4) for 30 min at 370C before staining with anti-VDIPEN IgG. The cartilage GAG content of adjacent sections was also determined by toluidine blue staining as previously described (54). Photomicrographs were made at 10-25x with a Leitz Vario Orthomat microscope.
Image analysis. Induction of VDIPEN epitope and depletion of GAGs in CIA and PGIA mouse hind paw AC were measured semiquantitatively at 10-20x on a Zeiss Axioscope fitted with a Kodak Megaplus camera (1,024 X 1,024 pixels) using the Presage CV-6 digital image analysis system (Advanced Imaging, Princeton, NJ). Areas exhibiting endogenous VDIPEN epitope were manually traced, and the mean pixel gray level (range of 0-255) of these regions was determined. Background densities, measured on adjacent sections stained using normal rabbit IgG as the primary antibody, were subtracted from each determination. Endogenous VDIPEN densities were expressed as a percent of the maximum VDIPEN staining obtained for uninvolved hyaline cartilage (HC) measured after exhaustive SLN digestion of adjacent sections. Similarly, GAG depletion was expressed as the mean pixel density of toluidine blue-labeled HC divided by the pixel density of normal toluidine blue-stained HC observed in nearby sections.
Results
Anti-VDIPEN IgG specifically labels a neoepitope in SLNtreated normal mouse cartilage. Normal murine articular cartilage contains a very thin hyaline zone that is rich in GAGs but lacks detectable staining with anti-VDIPEN IgG, even after digestion of the cryosection with chondroitinase-ABC (Fig. 1,  A-C) . However, SLN digestion of unfixed mouse paw cryosections induces intense anti-VDIPEN staining within the GAGrich pericellular (PC) matrix of chondrocytes and at the articular cartilage surface (Fig. 1, B and D) ; moderate VDIPEN labeling is also induced in the interterritorial zones of the AC (Fig. 1  D) . Preincubation of anti-VDIPEN IgG with 250 ng/ml YTG-EDFVDIPEN peptide completely blocked this labeling, whereas similar quantities of the spanning peptide (YTGEDFVDIPEN-FFGV) failed to inhibit staining ( Fig. 1, E Fig. 1 B) , and induced pericellular VDIPEN labeling was strikingly codistributed with high concentrations of PC GAGs (compare Fig. 3 B with Fig.  1 B) . Infiltrating inflammatory cells and cartilage erosion were also not detected at 10 d. In contrast, intense VDIPEN immunostaining was widespread at the articular surfaces of various tarsal and metatarsal joints of stage 2 paws at 20 d (Fig. 3, D-K) . VDIPEN epitope appeared to be induced and heavily concentrated in the pericellular matrices of AC chondrocytes and at the eroding outer surface of the articular cartilage (Fig. 3, D, I , and K). Moderate VDIPEN labeling was also present in the interterritorial zones of AC (Fig. 3, D and I) . Induction of intense VDIPEN staining correlated with marked depletion of GAGs throughout the AC of adjacent cryosections at this stage of CIA (Fig. 3, D and E) . Erosion of the AC and infiltration with inflammatory cells and pannus were now very evident (Fig. 3, D-G) . The invading pannus sometimes showed strong VDIPEN staining (Fig. 3 G) Fig. 1 D) . Predigestion of the sections with chondroitinase-ABC increased the staining intensity but did not alter the VDIPEN-staining pattern (not shown), indicating that this enzyme enhances accessibility of epitope to antibody and that it does not induce a loss of epitope-bearing aggrecan fragments. Endogenous VDIPEN staining was completely blocked by preincubating anti-VDIPEN IgG with YTGEDFVDIPEN (Fig. 3  H) but not by pretreatment with YTGEDFVDIPENFFGV (not shown); nonimmune rabbit IgG did not generate any immunoperoxidase labeling (Fig. 3 J) . This pattern of VDIPEN staining in CIA cartilage is highly specific, thus indicating that crossreactive epitopes are probably not being generated by other proteases during advanced disease.
Comparison with PGIA mice. Because PGIA appears to be a more chronic model than CIA, with waxing and waning clinical symptoms that progressively worsen 1-5 mo after immunization (18) , experiments were also conducted on paws of PGIA mice. One month after disease onset, intense VDIPEN staining was present in AC (Fig. 4 A) and was most concentrated in its pericellular matrix (Fig. 4 B) . Marked GAG depletion was present in corresponding AC regions observed in adjacent sections (Fig. 4 C) . Similar patterns were observed after 5 mo of disease, whereas normal BALB/c mouse AC lacked significant endogenous VDIPEN epitope (not shown).
Morphometry of VDIPEN induction and GAG depletion.
Semiquantitative histomorphometric measurements were performed using digital image analysis to compare the degrees of articular cartilage VDIPEN induction and GAG depletion observed between days 10 and 20 in CIA with corresponding levels found in PGIA (Fig. 5) Using image analysis, we recently observed that SLN digestion of normal paw cryosections generates a VDLPEN signal in AC more readily than a GAG depletion of equivalent magnitude could be produced (Donatelli, S. A., and Bayne, E. K., unpublished data). Thus, the early appearance of VDIPEN staining before overt GAG depletion found at 10 d in CIA may be due to differences in the sensitivity of the methods used here. Appearance of a SLN-mediated VDIPEN-positive signal depends on generation of the VDIPEN COOH-terminus in the interglobular region of aggrecan, followed by anti-VDIPEN staining and amplification via the immunoperoxidase-ABC technique. In comparison, detection of SLN-dependent GAG depletion requires cleavage and diffusion of enough GAG-containing aggrecan fragments out of the articular cartilage to create a reduction in staining with an unamplified metachromatic dye (toluidine blue). It is therefore possible that some GAG depletion also occurs in the early stages of AC damage in CIA but may not be as readily detectable as VDIPEN induction.
When the MMPs SLN, CLN, GLN-A, and GLN-B were evaluated for VDIPEN generation using intact aggrecan as a substrate, only SLN and GLN-A generated an epitope recognized by VDIPEN antibody; non-MMPs did not produce a VDIPEN signal (46, 47) . However, other MMPs such as GLN-B, interstitial or neutrophil CLN, and PUMP may also generate a VDIPEN COOH-terminus using a proteolyticially derived Gi-G2 fragment of porcine aggrecan as a substrate (56) (57) (58) . GLN-A is constituitively expressed in normal human synovia and is not up-regulated in disease, whereas SLN is dramatically induced in both RA and OA. These observations suggest that SLN may play a more dominant role than GLN-A in aggrecan catabolism in human arthritis (14 Bar for A, 100 gim; bar for B and C, 50 im.
to localize them and to determine the time course during which the enzymes they represent may play a role in aggrecan cleavage. In any case, our observation of VDIPEN induction is the first to localize any specific aggrecan degradation product in an arthritis model and is the most direct evidence that MMP-mediated aggrecan degradation does take place in situ in CIA and PGIA. At minimum, our observation of VDIPEN induction is the most specific evidence for the involvement of MMP activity in animal models of arthritis available to date. The chondrocyte PC matrix is rich in aggrecan and hyaluronan (50, 63) and also exhibits elevated PG synthesis (35). These observations correlate with the enriched GAG content that we observed in murine PC matrix and with the preferential induction of PC VDIPEN labeling found in normal AC after SLN digestion. Intense endogenous VDIPEN staining was localized in the AC chrondrocyte PC matrix in both CIA and PGIA, during the early phases of disease when inflammatory cells were not detectable in the synovial cavity. The induction of an aggrecan neoepitope at this strategic location suggests that cytokines generated during inflammatory arthritis stimulate chondrocytes to synthesize and secrete MMPs, which initiate destruction of extracellular matrix by cleaving aggrecan. Therefore, the early appearance of VDIPEN labeling in PC matrix is a highly sensitive indicator of the commencement of joint pathology initiated by chondrocytes. Additional chondrocytegenerated proteases not detected by our VDIPEN antibody also participate in aggrecan and CII degradation within the pericellular matrix (52, 60, 62) . The later appearance of VDIPEN labeling at the articular surface further suggests that MMPs originating from the synovial cavity and pannus may also participate in destruction of articular cartilage. Other ECM-degrading proteases secreted by inflammatory cells could also increase accessibility of the superficial AC to MMPs, thus enhancing further VDIPEN labeling at the articular surface. The recent localization of VDIPEN staining in damaged regions of human RA and OA cartilage also indicates that the VDIPEN neoepitope is a relevant marker of MMP-mediated aggrecan catabolism in human disease (64) . Analogous observations have also been reported for degradation of CII in organ culture and arthritic 2184 Singer et al.
O -I -r human cartilage (52) . Further studies of animal and arthritic patient cartilage using immunocytochemical methods to detect aggrecan neoepitopes generated by active MMPs and other proteases as described here should clarify further the role of these enzymes in the chondrodestructive process.
